2pnr Citations

Crystal structure of an asymmetric complex of pyruvate dehydrogenase kinase 3 with lipoyl domain 2 and its biological implications.

J Mol Biol 370 407-16 (2007)
Cited: 16 times
EuropePMC logo PMID: 17532006

Abstract

A homodimer of pyruvate dehydrogenase kinase (PDHK) is an integral part of pyruvate dehydrogenase complex (PDC) to which it is anchored primarily through the inner lipoyl-bearing domains (L2) of transacetylase component. The catalytic cycle of PDHK and its translocation over the PDC surface is thought to be mediated by the "symmetric" and "asymmetric" modes, in which the PDHK dimer binds to two and one L2-domain(s), respectively. Whereas the structure of the symmetric PDHK/L2 complex was reported, the structural organization and functional role of the asymmetric complex remain obscure. Here, we report the crystal structure of the asymmetric PDHK3/L2 complex that reveals several functionally important features absent from the previous structures. First, the PDHK3 subunits have distinct conformations: one subunit exhibits "open" and the other "closed" configuration of the putative substrate-binding cleft. Second, access to the closed cleft is additionally restricted by local unwinding of the adjacent alpha-helix. Modeling indicates that the target peptide might gain access to the PDHK active center through the open but not through the closed cleft. Third, the ATP-binding loop in one PDHK3 subunit adopts an open conformation, implying that the nucleotide loading into the active site is mediated by the inactive "pre-insertion" binding mode. Altogether our data suggest that the asymmetric complex represents a physiological state in which binding of a single L2-domain activates one of the PDHK protomers while inactivating another. Thus, the L2-domains likely act not only as the structural anchors but also modulate the catalytic cycle of PDHK.

Articles - 2pnr mentioned but not cited (1)

  1. A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Kennerson ML, Yiu EM, Chuang DT, Kidambi A, Tso SC, Ly C, Chaudhry R, Drew AP, Rance G, Delatycki MB, Züchner S, Ryan MM, Nicholson GA. Hum Mol Genet 22 1404-1416 (2013)


Reviews citing this publication (7)

  1. Regulation of pyruvate metabolism and human disease. Gray LR, Tompkins SC, Taylor EB. Cell Mol Life Sci 71 2577-2604 (2014)
  2. The pyruvate dehydrogenase complexes: structure-based function and regulation. Patel MS, Nemeria NS, Furey W, Jordan F. J Biol Chem 289 16615-16623 (2014)
  3. Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? Zhang W, Zhang SL, Hu X, Tam KY. Int J Biol Sci 11 1390-1400 (2015)
  4. Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents. Zhang SL, Hu X, Zhang W, Yao H, Tam KY. Drug Discov Today 20 1112-1119 (2015)
  5. Interplay Between m6A RNA Methylation and Regulation of Metabolism in Cancer. Mobet Y, Liu X, Liu T, Yu J, Yi P. Front Cell Dev Biol 10 813581 (2022)
  6. Unstructured regions of large enzymatic complexes control the availability of metabolites with signaling functions. Skalidis I, Tüting C, Kastritis PL. Cell Commun Signal 18 136 (2020)
  7. Mitochondrial Alpha-Keto Acid Dehydrogenase Complexes: Recent Developments on Structure and Function in Health and Disease. Szabo E, Nagy B, Czajlik A, Komlodi T, Ozohanics O, Tretter L, Ambrus A. Subcell Biochem 104 295-381 (2024)

Articles citing this publication (8)